Kratom (or Mitragyna speciosa) is a tropical psychoactive plant native to Southeast Asia [1]. It has gained global attention as a potential alternative for pain management, particularly in the United States [2–4].
Traditionally used for fatigue and analgesia (pain relief), kratom contains bioactive alkaloids — primarily mitragynine and 7-hydroxymitragynine — that interact with opioid receptors and other neurochemical systems [3]. For a deeper overview of these mechanisms, see our guide to how kratom works in the body.
In an era marked by opioid-related harms and unmet needs in chronic pain management, kratom has been positioned by some as a “natural” analgesic option. However, the scientific evidence base is still developing and heterogeneous. A central challenge is reconciling promising preclinical signals with limited and methodologically constrained human data.
This article examines three pillars of the evidence: animal (preclinical) studies, observational and self-report human data, and clinical trials, as well as key research gaps.
Is There Mechanistic Plausibility for Kratom in Pain Management?
The primary alkaloid in kratom, mitragynine, acts as a partial agonist at μ-opioid receptors [5–7]. Unlike classical opioids, it appears to produce less β-arrestin recruitment [8], a signaling pathway suggested to be linked with respiratory depression and other adverse effects.
Preclinical pharmacology supports the idea that kratom-derived compounds could function as analgesics with a distinct safety profile. However, mechanistic plausibility alone does not establish clinical efficacy.
Evidence from Animal Studies: A Potential Analgesic Signal
Several decades of research have produced a substantial body of preclinical studies on kratom and its alkaloids in pain models.
Animal studies typically assess pain using thermal assays, chemical or inflammatory models, or neuropathic pain paradigms. Across these models, kratom-derived compounds demonstrate dose-dependent antinociceptive effects [9].
These findings suggest that kratom can reduce pain-related behaviors across acute, inflammatory, and neuropathic conditions. Importantly, these effects are reversed by opioid antagonists, supporting the involvement of μ-opioid receptors [9].
The strengths of this evidence include mechanistic coherence, reproducibility across models, and consistent biological activity across different types of pain. However, important limitations remain: rodent models do not fully replicate human chronic pain, dosing and metabolism differ across species, and many studies use isolated alkaloids or high doses that may not reflect real-world use.
Overall, animal studies provide a strong proof-of-concept signal, but they do not establish clinical efficacy in humans.
Findings from Observational Studies in Humans
Most human data on kratom comes from observational research, including surveys, cross-sectional studies, and ecological momentary assessment (EMA).
These studies consistently show that pain is one of the most common reasons for kratom use [3,10], often among individuals with limited access to conventional pain treatments [3]. For more context on how kratom is used across different pain types, see our article on kratom for acute vs. chronic pain.
In one study of approximately 400 kratom users, around 49% met criteria for chronic pain, and pain relief was the most frequently reported motivation for use [3]. Many participants reported moderate to substantial pain relief, improved daily functioning, and reduced reliance on prescription opioids.
Across the broader literature, self-medication for pain and related conditions is commonly reported [11]. These findings reflect real-world use patterns and capture patient-reported outcomes that are often absent from controlled trials.
However, observational data have important limitations. These studies lack control groups, meaning causality cannot be established. Self-reported outcomes are inherently subjective and may be influenced by placebo effects or expectation bias. Additionally, confounding variables — such as concurrent substance use or mental health factors — may influence outcomes.
Notably, observational studies do not consistently show a clear relationship between pain severity and kratom use patterns, raising questions about dose-response relationships [3].
Despite these limitations, the consistency of reported benefits across diverse populations suggests a signal that warrants further controlled investigation.
What Does the Clinical Evidence Suggest?
Randomized controlled trials (RCTs) remain the gold standard for evaluating efficacy, but for kratom, they are currently limited in number and scope.
A recent systematic review identified only two RCTs conducted in healthy volunteers rather than pain patients [12,13].
In these studies, isolated mitragynine did not significantly alter pain threshold or tolerance [12]. Kratom preparations (such as decoctions) produced modest increases in pain tolerance, but these findings were observed in experimental settings rather than clinical pain conditions [13].
These results highlight a gap between the robust effects observed in animal studies and the limited or inconclusive findings in controlled human research.
Possible explanations include differences between isolated compounds and whole-plant preparations, challenges in dosing and pharmacokinetics, and the use of experimental pain models that may not reflect real-world chronic pain.
Overall, clinical evidence remains limited and not yet definitive regarding kratom’s effectiveness for pain.
Safety Considerations: What We Do and Don’t Know
While this article focuses on efficacy, safety remains an essential consideration.
Short-term controlled studies suggest that single doses are generally well tolerated, with mostly mild adverse effects [9,14]. However, longer-term and real-world concerns include the risk of dependence and withdrawal [15], potential drug interactions (including CYP450 metabolism) [16], and reported cases of toxicity, often involving adulterated products [17].
Importantly, long-term safety data remain limited, particularly in populations using kratom for chronic pain [18,19].
Conclusion
The current evidence on kratom for pain reflects a familiar pattern in early-stage research: biological plausibility and consistent real-world use alongside limited controlled clinical validation.
Animal studies demonstrate clear analgesic and anti-inflammatory effects, supporting a coherent mechanistic rationale. Observational data suggest widespread use and perceived benefit, particularly among individuals with unmet pain management needs.
At the same time, clinical evidence remains limited and does not yet provide definitive support for efficacy in pain populations. Long-term safety data are also still developing.
As such, kratom does not yet meet the threshold for an evidence-based pain treatment. However, the convergence of mechanistic plausibility and consistent user-reported outcomes highlights an important area for future research.
Moving forward, well-designed, adequately powered clinical trials — particularly those using standardized alkaloid preparations — will be essential to clarify both efficacy and safety.
Until then, claims about kratom’s analgesic effects should be interpreted with appropriate caution, while recognizing the need for continued investigation in this evolving field.
References
[1] Z. Hassan, M. Muzaimi, V. Navaratnam, N.H.M. Yusoff, F.W. Suhaimi, R. Vadivelu, B.K. Vicknasingam, D. Amato, S. Von Hörsten, N.I.W. Ismail, N. Jayabalan, A.I. Hazim, S.M. Mansor, C.P. Müller, From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction, Neuroscience & Biobehavioral Reviews 37 (2013) 138–151. https://doi.org/10.1016/j.neubiorev.2012.11.012.
[2] T. Emerick, S. Durbhakula, M.R. Eibel, L. Kohan, Kratom: a primer for pain physicians, Current Opinion in Anaesthesiology 37 (2024) 575–580. https://doi.org/10.1097/ACO.0000000000001413.
[3] C.J. Mun, L.V. Panlilio, K.E. Dunn, J. Thrul, C.R. McCurdy, D.H. Epstein, K.E. Smith, Kratom (Mitragyna speciosa) use for self-management of pain: Insights from cross-sectional and ecological momentary assessment data, The Journal of Pain 26 (2025) 104726. https://doi.org/10.1016/j.jpain.2024.104726.
[4] J.M. Rogers, K.E. Smith, J.C. Strickland, D.H. Epstein, Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample, Front. Pharmacol. 12 (2021) 789075. https://doi.org/10.3389/fphar.2021.789075.
[5] A.C. Kruegel, M.M. Gassaway, A. Kapoor, A. Váradi, S. Majumdar, M. Filizola, J.A. Javitch, D. Sames, Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators, J. Am. Chem. Soc. 138 (2016) 6754–6764. https://doi.org/10.1021/jacs.6b00360.
[6] S.E. Hemby, S. McIntosh, F. Leon, S.J. Cutler, C.R. McCurdy, Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7‐hydroxymitragynine, Addiction Biology 24 (2019) 874–885. https://doi.org/10.1111/adb.12639.
[7] M.P.G. Calvache, S. Obeng, F. Leon, L.R. Gamez‐Jimenez, A. Patel, N.P. Ho, M.L. Crowley, V. Pallares, M. Mottinelli, C.R. McCurdy, L.R. McMahon, T. Hiranita, In Vitro and In Vivo Pharmacological Comparison of Mu‐Opioid Receptor Activity of the Kratom ( Mitragyna speciosa ) Alkaloid Mitragynine and its Metabolite 7‐Hydroxymitragynine, Alzheimer’s & Dementia 17 (2021) e058605. https://doi.org/10.1002/alz.058605.
[8] D.A. Todd, J.J. Kellogg, E.D. Wallace, M. Khin, L. Flores-Bocanegra, R.S. Tanna, S. McIntosh, H.A. Raja, T.N. Graf, S.E. Hemby, M.F. Paine, N.H. Oberlies, N.B. Cech, Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions, Sci Rep 10 (2020) 19158. https://doi.org/10.1038/s41598-020-76119-w.
[9] C.S. Waloejo, P.S. Airlangga, B.P. Semedi, A.S. Veterini, K.H. Santoso, M.G.R. Pandin, D. Susila, S.S. Sulistiawan, C.H.P.A. Sumantrie, A.N.D. Anwar, G.P.A. Anindito, R.K. Noviandomo, D.A.P. Musalim, D.S. Budi, Kratom (Mitragyna speciosa) for pain management: a systematic review of preclinical evidence and limited clinical data, Phytomedicine Plus 6 (2026) 100983. https://doi.org/10.1016/j.phyplu.2026.100983.
[10] K.E. Smith, T. Lawson, Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program, Drug and Alcohol Dependence 180 (2017) 340–348. https://doi.org/10.1016/j.drugalcdep.2017.08.034.
[11] E. Prevete, K.P.C. Kuypers, E.L. Theunissen, G. Esposito, J.G. Ramaekers, M. Pasquini, O. Corazza, Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review, Curr Addict Rep 10 (2023) 317–334. https://doi.org/10.1007/s40429-023-00478-3.
[12] E. Prevete, E.L. Theunissen, K.P.C. Kuypers, R. Paci, J.T. Reckweg, M. Cavarra, S.W. Toennes, S. Ritscher, G. Bersani, O. Corazza, M. Pasquini, J.G. Ramaekers, An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans, Psychopharmacology 242 (2025) 1363–1376. https://doi.org/10.1007/s00213-024-06734-2.
[13] B. Vicknasingam, W.T. Chooi, A.A. Rahim, D. Ramachandram, D. Singh, S. Ramanathan, N.S.M. Yusof, H. Zainal, V. Murugaiyah, R. Gueorguieva, S.M. Mansor, M.C. Chawarski, Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study, Yale J Biol Med 93 (2020) 229–238.
[14] M.A. Huestis, J. Bothmer, T. Hudzik, J.E. Henningfield, S. Swift, Safety and Tolerability of Single and Multiple Daily Oral Doses of Dried Kratom Leaf Powder in a Randomized Trial in Healthy Volunteers, Therapeutic Drug Monitoring (2026). https://doi.org/10.1097/FTD.0000000000001427.
[15] D. Saingam, D. Singh, A.F. Geater, S. Assanangkornchai, W. Jitpiboon, C. Latkin, The Health Impact of Long-Term Kratom ( Mitragyna Speciosa ) Use in Southern Thailand, Substance Use & Misuse 58 (2023) 1212–1225. https://doi.org/10.1080/10826084.2023.2215301.
[16] R.S. Tanna, D.-D. Tian, N.B. Cech, N.H. Oberlies, A.E. Rettie, K.E. Thummel, M.F. Paine, Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations, The Journal of Pharmacology and Experimental Therapeutics 376 (2021) 64–73. https://doi.org/10.1124/jpet.120.000270.
[17] J.E. Henningfield, D.W. Wang, M.A. Huestis, Kratom Abuse Potential 2021: An Updated Eight Factor Analysis, Front. Pharmacol. 12 (2022) 775073. https://doi.org/10.3389/fphar.2021.775073.
[18] G. Papadi, N. Bakhiya, K. Ildico Hirsch‐Ernst, Assessment of the possible health risks associated with the consumption of botanical preparations of Mitragyna speciosa (kratom), EFS2 20 (2022). https://doi.org/10.2903/j.efsa.2022.e200415.
[19] E. Prevete, K.P.C. Kuypers, E.L. Theunissen, O. Corazza, G. Bersani, J.G. Ramaekers, A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans, Human Psychopharmacology 37 (2022) e2805. https://doi.org/10.1002/hup.2805.
